A. Hoering

发表

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

J. Crowley, G. Mulligan, D. Esseltine, 2016, Cancer cell.

A Comparative Study on the SWOG Two-Stage Design Extension to Stop Early for Efficacy in Single Arm Phase II Trials

J. Crowley, A. Hoering, Monica Chaudhari, 2020 .

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood Cancer Journal.

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.

Faith, G. Morgan, P. Sonneveld, 2008, Blood.

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy

S. George, K. Ballman, Shreyaskumar R Patel, 2018, Sarcoma.

Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma

B. Barlogie, G. Morgan, M. Zangari, 2016, Clinical Cancer Research.

Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival

M. Steinbach, Vipin Kumar, B. Barlogie, 2008, BMC medicine.

Experimental design and analysis of antibody microarrays: applying methods from cDNA arrays.

T. Therneau, J. Eckel-Passow, I. Ghobrial, 2005, Cancer research.

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.

W. S. Hlavacek, A. Maitra, M. Hidalgo, 2017, Journal of gastrointestinal oncology.

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma

J. Crowley, Hongwei Wang, B. Durie, 2017, Future oncology.

Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels

O. Stephens, B. Barlogie, J. Shaughnessy, 2013, PloS one.

Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120

B. Barlogie, M. Dhodapkar, R. Orlowski, 2020, Clinical Cancer Research.

Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes

B. Barlogie, G. Morgan, M. Zangari, 2018, British journal of haematology.

Oncology clinical trials

P. Müller, T. Lai, G. Rosner, 2013 .

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood cancer journal.

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols

B. Barlogie, J. Shaughnessy, J. Sawyer, 2012, Leukemia.

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

B. Barlogie, F. van Rhee, Y. Alsayed, 2012, Haematologica.

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma

J. Crowley, B. Barlogie, K. Stratton, 2014, Leukemia.

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

T. Willis, B. Barlogie, G. Morgan, 2017, Haematologica.

Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.

J. Cortes, J. Kolitz, R. Stone, 2016 .

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

T. Zimmerman, M. Dhodapkar, P. Richardson, 2021, The Lancet. Haematology.

Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.

B. Barlogie, M. Dhodapkar, M. Gertz, 2009, Blood.

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

G. Rosner, A. Chaudhuri, G. Pennello, 2022, JCO precision oncology.

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

B. Barlogie, J. Shaughnessy, M. Dhodapkar, 2011 .

Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma

G. Morgan, D. Auclair, J. Keats, 2019, Haematologica.

Thalidomide therapy in adult patients with myelodysplastic syndrome

S. Alberts, A. Tefferi, S. Geyer, 2006, Cancer.

Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy

B. Barlogie, G. Tricot, M. Zangari, 2008, Haematologica.

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.

P. Bulur, S. Vuk-Pavlović, A. Tefferi, 2006, Cytotherapy.

High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse

B. Barlogie, G. Morgan, M. Zangari, 2021, British journal of haematology.

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

B. Freidlin, S. Jagannath, P. Richardson, 2022, Blood Cancer Journal.

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).

A. Maitra, V. Bolejack, P. O'dwyer, 2014 .

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

F. Zhan, B. Barlogie, J. Shaughnessy, 2007, Clinical Cancer Research.

Curing Multiple Myeloma (MM) with Total Therapy (TT)

B. Barlogie, G. Morgan, M. Zangari, 2014 .

Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115

B. Barlogie, R. Orlowski, K. Finn, 2013, Bone Marrow Transplantation.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Robert K. Stuart, Antje Hoering, Arthur C. Louie, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

D. Campana, B. Barlogie, J. Shaughnessy, 2012, Haematologica.

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

B. Barlogie, G. Morgan, E. Tian, 2020, Clinical Cancer Research.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project

B. Barlogie, G. Morgan, J. Miguel, 2018, Blood Cancer Journal.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

H. Goldschmidt, G. Morgan, A. Palumbo, 2012, Leukemia.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

H. Goldschmidt, G. Morgan, A. Palumbo, 2012, Leukemia.

Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns

B. Barlogie, G. Morgan, M. Zangari, 2020, Blood Cancer Journal.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Pingping Qu, Fadi Towfic, Konstantinos Mavrommatis, 2018, Leukemia.

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

B. Barlogie, A. Dispenzieri, S. Rajkumar, 2017, The Lancet.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

H. Goldschmidt, G. Morgan, H. Einsele, 2018, Blood.

1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma

Pingping Qu, Fadi Towfic, Konstantinos Mavrommatis, 2018 .

Handbook of Statistics in Clinical Oncology, Second Edition

John Crowley, Antje Hoering, J. Crowley, 2005 .

Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.

Dafydd G. Thomas, E. Fearon, R. Menon, 2016, Cancer research.

Adult B-Cell Lymphomas With Burkitt-Like Morphology Are Phenotypically and Genotypically Heterogeneous With Aggressive Clinical Behavior

T. Habermann, G. Dewald, A. Hoering, 2005, The American journal of surgical pathology.

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

B. Barlogie, A. Dispenzieri, S. Rajkumar, 2020, Blood Cancer Journal.

Randomized Phase III Clinical Trial Designs for Targeted Agents

Antje Hoering, M. LeBlanc, J. Crowley, 2008, Clinical Cancer Research.

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma

B. Barlogie, G. Morgan, M. Zangari, 2018, Haematologica.

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

B. Barlogie, G. Morgan, E. Tian, 2016, Clinical Cancer Research.

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.

B. Barlogie, D. Johann, J. Sawyer, 2013, Blood.

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.

B. Barlogie, E. Anaissie, T. Bartel, 2013, Blood.

patients treated since 1989 stem-cell mobilization: the Arkansas experience in more than 3000 autotransplantation for multiple myeloma linked to poor hematopoietic Cytogenetically defined myelodysplasia after melphalan-based

B. Barlogie, E. Anaissie, G. Tricot, 2013 .

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

B. Barlogie, Y. Alsayed, J. Crowley, 2013, Leukemia.

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2010, Blood.

Suppression of abnormal karyotype predicts superior survival in multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2008, Leukemia.

ORIGINAL ARTICLE Suppression of abnormal karyotype predicts superior survival in multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2008 .

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.

B. Barlogie, E. Anaissie, G. Tricot, 2008, Blood.

On the analysis of viral load endpoints in HIV vaccine trials

Michael G Hudgens, Antje Hoering, Steven G Self, 2003, Statistics in medicine.

Long-term outcomes after autologous stem cell transplantation for multiple myeloma.

B. Barlogie, G. Morgan, M. Zangari, 2020, Blood advances.

Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy.

M. Hirsch, J. Schmitz, M. Kuroda, 2001, The Journal of infectious diseases.

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, Blood.

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

B. Barlogie, J. Shaughnessy, M. Dhodapkar, 2014, Blood.

Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials

David J. Reiss, B. Barlogie, G. Morgan, 2020, PLoS medicine.

First thalidomide clinical trial in multiple myeloma: a decade.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2008, Blood.

Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal

S. Usmani, A. Hoering, 2013, Leukemia.

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

J. Crowley, B. Barlogie, G. Morgan, 2016, Blood Cancer Journal.

Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents

Antje Hoering, M. LeBlanc, J. Crowley, 2010, Clinical Cancer Research.

SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)

T. Zimmerman, P. Richardson, N. Callander, 2014 .

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood Cancer Journal.

Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma

O. Stephens, B. Barlogie, J. Shaughnessy, 2009, Leukemia.

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2008, Leukemia.

Clinical trial designs for multiple myeloma.

J. Crowley, A. Hoering, 2007, Clinical advances in hematology & oncology : H&O.

The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling

B. Barlogie, E. Tian, M. Zangari, 2015, Leukemia.

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

B. Barlogie, F. van Rhee, J. Crowley, 2012, Blood.

follow-up of Southwest Oncology Group Long-term survival in Waldenstrom macroglobulinemia: 10-year

B. Barlogie, M. Dhodapkar, M. Gertz, 2013 .

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

J. Crowley, B. Barlogie, G. Morgan, 2015, Haematologica.

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2010, Blood.

Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

M. Dhodapkar, P. Richardson, S. Rajkumar, 2020 .

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

G. Morgan, M. Zangari, B. Walker, 2019, Blood.

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

B. Barlogie, G. Morgan, G. Tricot, 2019, Blood.

Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma

E. Rohren, R. Orlowski, P. Voorhees, 2020, Clinical Cancer Research.

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434

B. Barlogie, R. Orlowski, G. Srkalović, 2014, Cancer medicine.

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

B. Barlogie, J. Shaughnessy, E. Anaissie, 2012, Clinical Cancer Research.

variable in terms of both onset and duration in Total Therapy protocols Complete remission in multiple myeloma examined as time-dependent

B. Barlogie, J. Shaughnessy, E. Anaissie, 2012 .

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, Blood.

Risk of multiple myeloma in a case–spouse study

R. Hoover, G. Morgan, B. V. Van Ness, 2016, Leukemia & lymphoma.

Reply to J. Mehta

J. Crowley, B. Barlogie, J. Shaughnessy, 2011 .

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2012, Leukemia.

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

B. Barlogie, D. Johann, F. van Rhee, 2013, Haematologica.

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

R. Orlowski, B. Durie, S. Usmani, 2020 .

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2008, Blood.

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols

B. Barlogie, E. Anaissie, J. Shaughnessy, 2011, Cancer.

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.

J. Crowley, B. Barlogie, J. Shaughnessy, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

Pingping Qu, Bart Barlogie, Antje Hoering, 2017, Haematologica.

Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx)

B. Barlogie, D. Johann, J. Epstein, 2013 .

Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma

G. Morgan, D. Auclair, J. Keats, 2019, Haematologica.

Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups

B. Barlogie, G. Morgan, M. Dhodapkar, 2021, Leukemia.

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

J. Crowley, B. Barlogie, J. Epstein, 2013, Leukemia.

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

Razelle Kurzrock, Antje Hoering, Vincent Chung, 2013, Cancer Chemotherapy and Pharmacology.

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials

B. Barlogie, A. Dispenzieri, S. Rajkumar, 2018, Blood Cancer Journal.

The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma

B. Barlogie, G. Morgan, M. Zangari, 2018, Clinical Cancer Research.

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

R. Orlowski, M. Rosenzweig, J. Zonder, 2015, Blood Cancer Journal.

Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

A. Krishnan, P. Hari, R. Orlowski, 2020 .

B. Barlogie, A. Dispenzieri, S. Rajkumar, 2018, Blood Cancer Journal.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project

B. Barlogie, G. Morgan, J. Miguel, 2018, Blood Cancer Journal.

Multiple myeloma gammopathies A high-risk , Double-Hit , group of newly diagnosed myeloma identi fi ed by genomic analysis

H. Goldschmidt, G. Morgan, H. Einsele, 2018 .

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

David J. Reiss, B. Barlogie, G. Morgan, 2018, Blood.

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

Katherine K. Nishimura, F. van Rhee, D. Fajgenbaum, 2022, Blood advances.

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

B. Barlogie, G. Morgan, M. Zangari, 2015 .

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.

H. Goldschmidt, G. Morgan, P. Sonneveld, 2009 .

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

B. Barlogie, A. Dispenzieri, S. Rajkumar, 2015 .

Predictive Biomarkers and Personalized Medicine Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR 3 C 1

B. Barlogie, J. Shaughnessy, E. Anaissie, 2012 .

Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528.

D. Gandara, P. LoRusso, S. Gadgeel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents

Antje Hoering, Michael LeBlanc, Alan Mitchell, 2013, Clinical trials.

Final Results Of Phase II Study Of Pomalidomide (Pom) In GEP-Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

B. Barlogie, K. Stratton, J. Crowley, 2013 .

Efficacy for Targeted Agents Seamless Phase I-II Trial Design for Assessing Toxicity and

M. LeBlanc, J. Crowley, A. Hoering, 2011 .

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

Caleb K. Stein, B. Barlogie, G. Morgan, 2016, Blood Cancer Journal.

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials

B. Barlogie, A. Dispenzieri, S. Rajkumar, 2018, Blood Cancer Journal.

IASLC lung cancer staging project: the new database to inform revisions in the ninth edition of the TNM classification of lung cancer.

R. Rami-Porta, H. Asamura, K. Chansky, 2023, Journal of Thoracic Oncology.

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

D. Campana, B. Barlogie, J. Shaughnessy, 2012, Haematologica.

Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents

M. LeBlanc, J. Crowley, A. Hoering, 2010, Clinical Cancer Research.

Withdrawal of Life Sustaining Treatment After Resuscitation from Cardiac Arrest: Quo Vadis?

A. Hoering, Graham Nichol, Emily Goren, 2023, Resuscitation.

The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.

H. Goldschmidt, B. Barlogie, J. Shaughnessy, 2006 .

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, Blood.

Randomized Phase III Clinical Trial Designs for Targeted Agents

M. LeBlanc, J. Crowley, A. Hoering, 2008, Clinical Cancer Research.

Phase III Trials for Targeted Agents

M. LeBlanc, J. Crowley, A. Hoering, 2012 .

Combination Therapy with CC-5013 (Lenalidomide; Revlimid™) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).

R. Fonseca, A. Dispenzieri, S. Rajkumar, 2004 .

First thalidomide clinical trial in multiple myeloma: a decade.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2008, Blood.

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

B. Barlogie, G. Morgan, M. Zangari, 2016 .

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2010, Blood.